Waystar Stock Is Down 32% This Past Year, but One Fund Bought Up $11.5 Million Last Quarter

Blue Door purchased 322,600 Waystar shares on Feb 17, 2026 (estimated $11.49M); post-trade stake was 402,300 shares valued at $13.18M and the quarter-end position value rose by $10.15M. Waystar reported 2025 revenue of $1.10B (+17% YoY) and adjusted EBITDA of ~$462M (+21% YoY), with Q4 revenue +24% to ~$304M and guidance implying ~ $1.28B revenue and $535M adj EBITDA at the midpoint. Shares trade at $24.16, down ~31.5% Y/Y, so the trade signals conviction in healthcare SaaS despite recent share-price underperformance.

Analysis

Blue Door’s upweight is a bet that healthcare revenue-cycle software will re-rate relative to general-purpose enterprise software as buyers prioritize measurable ROI and margins over AI-driven hype. At the fund level this increases concentration in durable, recurring-revenue exposures and signals a preference for idiosyncratic growth that can survive a macro slowdown; the practical implication is more sensitivity to company-level execution and guidance than to broad software multiples.

Second-order winners include specialist RCM vendors and SaaS firms that can cross-sell into hospital finance stacks, while legacy consulting/service providers face downside if customers shift spend from implementation projects to subscription platforms. The move also raises M&A odds: a meaningful strategic or PE bid becomes a higher-probability path to valuation uplift if results stay steady — a near-term catalyst that could compress time-to-realization to 12–24 months.

Key risks are asymmetric: short-term sentiment can flip on a single guidance miss, but the larger, multi-year threats are regulatory shifts in reimbursement or rapid algorithmic automation that reduces billable feature sets. Monitor quarterly ARR/renewal metrics and churn closely over the next two quarters as the primary inflection points; a sustained beat trajectory plus improved gross retention materially increases the odds of a multiple expansion event.

Key Decisions for Investors

• Go long WAY via a limited-risk options structure: buy 12–18 month call LEAPs and sell a higher strike to fund half the premium (synthetic call spread). Size initial exposure to 1–2% of portfolio; target asymmetric upside of +35–60% if ARR/retention accelerates within 12 months, and cap max premium loss at 100% of that allocation.
• Pair trade to express idiosyncratic RCM conviction while hedging sector risk: long WAY (directional via call spread) vs short a basket of general-software names (equal-weighted EPAM and NICE) for a 12-month horizon. This reduces exposure to a broad software multiple rerate; if WAY outperforms peers by >20% in 6–12 months, trim to lock gains.
• Event-driven trade: establish a small long equity position in WAY ahead of the next two quarterly reports (size 0.5–1% portfolio) and set a tight stop at -15% and a take-profit at +40% tied to ARR/gross retention beats. If guidance is raised, scale to 2–3% and re-evaluate risk on M&A chatter.
• Risk management: avoid large one-way exposure. If regulatory or AI-driven disintermediation signals appear (material contraction in effective pricing or contract scope), flip to hedged/bearish stance by buying puts or selling covered calls to limit downside over the subsequent 3–6 months.